TP53 and obesity due to melanocortin 4 receptor deficiency: Therefore, p53-suppression-based approaches that beneficially reprogram adipocyte metabolic homeostasis in obesity may provide a new strategy for treating obesity and other metabolic diseases, including type II diabetes.